frenchv33921

@frenchv33921 · tracked since Mar 2026
Calls 3 46 Posts tracked · 0.7/day
Calls
7d 0
30d 3
90d 3
Best Calls
No live winners yet
Worst Calls
RANI long -12.9%
HALO long -4.6%
GMAB long -0.5%
Most Mentioned
ALSEC ×3
GMAB ×1
HALO ×1
Recent Calls
GMAB long 2 weeks ago
HALO long 2 weeks ago
RANI long 1 week ago
Win Rate 0% Long 3 Short 0
Win Rate
7d 0%
30d —
90d —
Average Return -6.0% Long Return -6.0% Short Return -
Average Return
7d -7.5%
30d —
90d —
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
RANI Rani The... Rani Therapeutics H...
Long
May 16
$1.08
-12.9%
Long $RANI (Rani Therapeutics) — clinical-stage pharma/medtech developing oral form for peptides/proteins, partnership with Chugai, cash runway until Q4 2027, MC $200M; potential buyout target. Speaker took a tiny speculative position.
Long $RANI (Rani Therapeutics) — clinical-stage pharma/medtech developing oral form for peptides/proteins, partnership with Chugai, cash runway until Q4 2027, MC $200M; potential buyout target. Speaker took a tiny speculative position.
Healthcare
TWITTER
GMAB Genmab A/S ADS Genmab A/S ADS
Long
May 12
$27.02
-0.5%
Long $GMAB (Genmab) — paired with HALO as a Darzalex revenue capture play; speaker holds both as siphons on Darzalex sales.
Long $GMAB (Genmab) — paired with HALO as a Darzalex revenue capture play; speaker holds both as siphons on Darzalex sales.
Healthcare
TWITTER
HALO Halozyme Halozyme
Long
May 12
$72.01
-4.6%
Long $HALO (Halozyme) — speaker massively reinforced position; sees HALO and GMAB as two siphons capturing Darzalex revenues.
Long $HALO (Halozyme) — speaker massively reinforced position; sees HALO and GMAB as two siphons capturing Darzalex revenues.
Healthcare
TWITTER
Showing 3 of 3 picks · sorted by mentions